Non-coding DNA in IBD: from sequence variation in DNA regulatory elements to novel therapeutic potential

Claartje Aleid Meddens, Amy Catharina Johanna van der List, Edward Eelco Salomon Nieuwenhuis, Michal Mokry

ABSTRACT
Genome-wide association studies have identified over 200 loci associated with IBD. We and others have recently shown that, in addition to variants in protein-coding genes, the majority of the associated loci are related to DNA regulatory elements (DREs). These findings add a dimension to the already complex genetic background of IBD. In this review we summarise the existing evidence on the role of DREs in IBD. We discuss how epigenetic research can be used in candidate gene approaches that take non-coding variants into account and can help to pinpoint the essential pathways and cell types in the pathogenesis of IBD. Despite the increased level of genetic complexity, these findings can contribute to novel therapeutic options that target transcription factor binding and enhancer activity. Finally, we summarise the future directions and challenges of this emerging field.

INFLAMMATORY BOWEL DISEASE
IBD is a group of disorders of the GI tract that are characterised by intermittent, chronic or progressive inflammation. There are two main groups of IBD: Crohn’s disease (CD) in which transmural inflammation of the intestinal wall occurs in patches throughout the whole intestine, and UC in which inflammation is limited to the mucosa of the colon and rectum. The pathogenesis of IBD is multifactorial and includes genetic susceptibility as a major contributor. Alongside the growing number of identified genetic variability for IBD, there is growing knowledge on the role and functions of many different elements that often reside outside of the protein-coding regions of the human genome. This impacts the interpretation of the role that these variants play in IBD pathogenesis. In this review, we will introduce the concept of DNA regulatory regions, elucidate the possible roles of non-coding regulatory DNA in IBD pathogenesis and discuss how this creates novel therapeutic possibilities.

Genetic susceptibility in IBD pathogenesis
It has been known for decades that both CD and UC show familial clustering, although in the absence of a clear Mendelian inheritance pattern. Therefore, both diseases are generally considered polygenic disorders with variable penetrance. Reported risk ratios for siblings of patients with CD and UC compared with the general population vary between 15–42 and 7–17, respectively. Three nationwide twin studies performed in Sweden, Denmark and the UK revealed increased concordance of IBD in monzygotic twins when compared with dizygotic twins, thereby elucidating that familial clustering is not solely based on shared environmental factors but rather on a shared genetic background. In CD, the difference in concordance is more pronounced than it is in UC, implying a greater genetic influence on the pathogenesis of CD than UC. The Swedish study further revealed significantly higher co-occurrence rates of phenotypic characteristics in monzygotic twins when compared with dizygotic twins, especially for age of onset and location of disease, suggesting that the disease and the phenotypic manifestations of IBD are heritable.

Based on these observations, a substantial effort was made to identify genetic elements involved in IBD pathogenesis. In this respect, multiple genome-wide association studies (GWAS) were performed over the past years. These studies assayed common genetic variants (single nucleotide polymorphisms [SNPs]) spanning the whole genome in search of SNPs that are significantly over-represented in patients when compared with healthy controls. SNPs that occurred more frequently in patients are thus called disease-associated variants. Many genetic loci and variants that are located side by side are inherited together during meiosis (ie, there is a very small change of the occurrence of recombination sites between them). Due to this phenomenon, associated SNPs are generally considered to be markers for other variants located in the coding region of nearby genes. This approach has led to the identification of numerous crucial genes and pathways involved in IBD pathogenesis and has allowed for the development of novel therapeutic approaches. GWAS meta-analyses have identified over 200 loci that are associated with IBD and account for the increased risk of development of the disease. Because the search for candidate genes at the associated loci has proven difficult, most loci are not yet functionally linked to IBD. There are indications that pathogenic processes between CD and UC are convergent and share the majority of their associated loci (eg, the IL23R locus).

Overall, IBD consists of a range of inflammatory disorders in the GI tract with distinctive onsets, severities, localisations and complications. Although
Recent advances in basic science

Figure 1 DNA regulating elements. (A) Promoter elements are located directly upstream of genes. By binding transcription factors and recruiting RNA polymerase II, promoters mediate the transcription. (B) Enhancer elements are located distally from the gene(s) they regulate(s). Active enhancer elements increase transcription levels, which is mediated through transcription factor binding. RNA POL II, RNA polymerase II; TF, transcription factor.

a clear role for genetic susceptibility in IBD pathogenesis has been identified through multiple GWAS, the translation of these findings into patient benefits has been limited. The majority of SNPs that are associated with IBD were found to be located in non-coding DNA. Therefore, these SNPs cannot be causative in the sense that they directly lead to amino acid changes at the protein level.6–12 18–21 Notably, knowledge on the functional non-coding elements in the human genome has tremendously increased. This knowledge can now be used to better interpret GWAS findings. Here we review new approaches in which the focus shifts from coding sequences to other functional parts of the human genome and how this further enhances our knowledge of causative IBD genetic mutations and the awaited therapeutic perspectives.

DNA REGULATORY ELEMENTS

Genomic DNA functions as a carrier of information that dictates the primary sequences of genes. In addition to this important function, non-coding DNA contains elements that are involved in transcriptional regulation.22 According to the 2013 University of California Santa Cruz (UCSC) genome build (GRCh38. p12, December 2013, last updated January 2018), the human genome consists of 3 609 003 417 base pairs and 20 376 coding genes.23 The coding sequences of genes make up only 2% of the whole genome, which designates 98% of the three billion base pairs as non-coding DNA.24 Over the last years, some functions of non-coding DNA have been discovered, and the role of regulatory sequences in transcriptional regulation, development, disease and determination of cell type specificity is now widely appreciated.25–28 Multiple distinct elements have been identified, each of which displays specific characteristics and plays different roles in transcriptional regulation (figure 1).

Enhancers

Enhancers are located distal from the genes they regulate and can be found up to several megabases away from the transcription start site.29 They are involved in enhancing the transcription of a regulated gene (figure 1A,B). These distal regulatory elements can regulate multiple genes and one gene can be regulated by multiple enhancers. The mechanisms of enhancer function have been studied at both the molecular (enhancement of transcription) and cellular (cell differentiation and development) levels. The mechanism through which enhancers regulate the transcription from promoters has been widely discussed.30 Multiple models have been proposed, and the ‘looping’ model received support after the development of a method known as chromosome conformation capture (3C). The looping model states that the action of enhancers relies on a physical interaction between the enhancer and the promoter of a reporter gene. Various 3C-based methods have been developed to enable the identification of genomic regions that are in physical contact with each other. By using these techniques, long-range interactions between enhancers and promoters have been discovered.31 In studies of the β-globin locus and its distant locus control region, specific interactions between enhancer-bound and promoter-bound transcription factors (TFs) have been discovered.32 33 Through these and other studies it is now generally accepted that enhancer function is established by TFs that bind to transcription factor binding sites (TFBS) and subsequently by the interaction between the TFs that are bound to promoters at one site and the TFs bound to enhancers at other sites.34

Enhancers play a key role in the establishment of complex expression patterns that determine the diversity of spatial and temporal gene expression within an organism.22 Enhancer activity is highly cell type-specific and can be correlated with gene expression patterns. Some enhancers can be found in clusters that drive the expression of cell type-specific genes. These clusters of enhancers are called super-enhancers and have been shown to be enriched in disease-associated variants.34 35 The combination of the histone modifications histone 3 lysine 4 monomethylation (H3K4me1) and histone 3 lysine 27 acetylation (H3K27ac) predominantly marks active enhancers, whereas H3K27 acetylation or H3K4me1 alone is predominantly found at ‘poised’ or inactive genes.36–38 Interestingly, many regulatory
elements can have both enhancer and promoter characteristics and can therefore show different histone marks in time, in cell types and cell states.\textsuperscript{39–43} By investigating H3K4me1 distribution, between 24,000 and 36,000 enhancers were identified per cell line. Surprisingly, only a minority of these locations (approximately 3000) overlapped between the two cell types examined, showing that enhancers exhibit cell type-specific patterns. The contribution of epigenetic signatures on development is further established by the finding that fetal gut shows distinct DNA methylation patterns and dynamics from paediatric and adult intestinal tissue.\textsuperscript{44} By identifying the divergent patterns of enhancer activity in different cell types within one organism, enhancer activity was shown to play an important role during differentiation and development.\textsuperscript{45,46}

Promoters

Promoters are regulatory elements that can be found at the 5'-end of a gene and are involved in transcription initiation. Promoter sequences contain TFBS that recruit (TFs) and assemble the transcription preinitiation complex that guides RNA polymerase II to the transcription start site. The location of promoters relative to genes, usually located just upstream of a gene, has facilitated their identification and annotation (figure 1A).\textsuperscript{38} Although active promoters are classically marked by histone 3 lysine 4 trimethylation (H3K4me3) and histone modifications, recent studies have shown that some elements can exhibit promoter activity for one gene and enhancer activity for another gene.\textsuperscript{39,41–43} As described above, one DNA regulatory element (DRE) can be marked by different histone modifications, which reflects the potential of elements to execute multiple regulatory functions.\textsuperscript{40} Promoters and enhancers might therefore no longer be seen as individual entities, but rather as a spectrum of DRE activity.\textsuperscript{41}

Next to enhancers and promoters, multiple other non-coding elements are involved in the regulation of gene expression. For example silencer and insulator elements are mainly involved in negative regulation of gene expression. As such, expression levels are subject to the composition of all sorts of elements along the chromosomes. In contrast to the cell type-specific activity of enhancer elements, the activity of most other elements is consistent throughout different cell types, as is reflected by their stable chromatin states.\textsuperscript{49}

MECHANISMS THROUGH WHICH VARIANTS IN DRE CAUSE HUMAN GENETICS DISEASE

Since the knowledge on DREs has increased, it has become clear that DREs are involved in determining cell types and differentiation. Sequence variants can be located in the whole genome, including DREs, and causative variants in both coding and non-coding elements are important players in the pathogenesis of complex genetic diseases such as IBD.

There are multiple ways through which sequence variants in DREs can contribute to the development of a genetic disease. One of the proposed mechanisms is through the alteration of TFBS. In this model, a sequence variant in the TFBS changes the affinity of a TF for this specific sequence. This can subsequently change the regulatory activity of DREs. Figure 2 shows an example of an altered nuclear factor kappa B (NFκB)-binding site in an enhancer that regulates the expression of the PTGER4 gene. The disruption of this binding site results in less binding of NFκB and subsequently a decreased expression of an IB-associated gene (PTGER4).\textsuperscript{40} Another mechanism through which variants can contribute to pathogenic processes is by their influence on DRE activity and corresponding histone modifications and DNA methylation profiles.\textsuperscript{51–55} Recently, these theoretical models were supported by the finding that allelic differences lead to allele-specific activity of many regulatory layers. Sequence variants were shown to affect transcription levels, binding of TFs, DNA methylation, histone modifications and histone positioning at the locus of the variant.\textsuperscript{56–58} Furthermore, this sequence-based variation in regulatory modules can be transmitted from parent to child, indicating that altered transcription regulation might be a basis for the heritable pathogenic processes.\textsuperscript{59,60}

Besides variants in DREs, there are variants in non-protein-coding DNA that result in a phenotype through different mechanisms. Variants that cause alternative splicing and thereby affect the protein structure have been described.\textsuperscript{65} Furthermore, variants in genes that code for microRNAs or long non-coding RNAs can affect the function of these non-coding RNAs and can thereby contribute to IBD pathogenesis.\textsuperscript{62,63}

Several pathogenic mechanisms through which non-coding DNA can result in disease phenotypes have been delineated in monogenic diseases. For example, preaxial polydactyly was found to be caused by a single mutation in a regulatory element of the Sonic hedgehog gene that is found 1 Mb upstream of the gene.\textsuperscript{65} This study and other studies\textsuperscript{64} demonstrate the possibility that even a single deleterious sequence variant in a regulatory region can cause disease. The mechanisms through which less common genetic variants (ie, deletions, translocations and so on) alter enhancer activity and contribute to genetic disease have been extensively reviewed.\textsuperscript{65}

Taken together, these data establish that sequence variants in non-coding DNA can influence the activity of regulatory elements and that such sequence variants are often associated with human genetic diseases.

THE MAJORITY OF IBD-ASSOCIATED VARIANTS MAP TO DREs

To understand the pathogenesis of IBD, the major contributors should be identified on the level of proteins, RNA transcripts and consequently genes. The genetic background of IBD has been successfully studied through GWAS, but unfortunately extracting the major players and causative genes is not straightforward. Initially, the translation of GWAS data into candidate genes focused on variants that could be linked to genes via their localisation in close proximity to the associated variant (figure 3A,B).\textsuperscript{11,19,20} However, the association of many variants that lie outside gene bodies cannot be linked to missense mutations.

As over 80% of the human genome consists of functional regulatory elements, it was hypothesised that the association of non-coding SNPs to IBD could be due to their effect on regulatory elements. Maurano\textit{et al.} determined the large overlap between GWAS-associated SNPs for multiple diseases and open chromatin (defined by DNase hypersensitivity sites [DHS]). DHS are a proxy for chromatin that is accessible for proteins such as TFs, and therefore active regulatory elements are generally found to map to DHS. This study revealed a significant enrichment of disease-associated SNPs to DHS and showed that these putative regulatory elements can interact with promoters over long genomic distances in vivo.\textsuperscript{52} Figure 3C shows how novel approaches can result in the identification of novel IBD candidate genes (eg, IL10RA) at previously associated loci. Disease-associated SNPs were also found to be enriched in a combination of DNase footprints, TFBS and histone modifications.\textsuperscript{66} The role of the chromatin landscape in IBD was further established by the
Recent advances in basic science

Figure 2  Influence of sequence variants on protein expression levels. The presence of an SNP in the TFBS of an active enhancer enables the enhancer to increase or decrease the transcription of genes. (A) Example of an SNP (rs4495224) that is associated with Crohn’s disease and is located in a TFBS in an enhancer element that regulated the expression of PTGER4. In silico analysis demonstrated that the C-allele of the rs4495224 polymorphism enables the binding of NFKB.50 (B) The A-allele of the rs4495224 polymorphism is thought to alter the TFBS in an enhancer, which will cause decreased affinity of NFKB. This could result in less enhancer activity and a subsequent decrease in PTGER4 expression levels. NFKB, nuclear factor kappa B; RNA POL II, RNA polymerase II; SNP, single nucleotide polymorphism; TF, transcription factor; TFBS, transcription factor binding site.

finding that the colon tissue of patients with CD can be subdivided into two clinically relevant subtypes based on chromatin accessibility profiles.67 To address whether loci specific for IBD localise to DRE, we profiled active regulatory elements in cell types that are relevant for IBD. We found that 56% of IBD-associated SNPs can be linked to either immune or intestinal epithelial cell-specific regulatory regions (as determined based on the presence of histone modifications).18 This colocalisation occurred approximately three times more frequently in IBD-associated SNPs when compared with randomised sets of SNPs. Furthermore, the enrichment of the localisation of IBD-associated SNPs in enhancers and promoters that are activated on active UC and CD has been revealed.68 These data suggest that a large part of the IBD-associated loci can be explained by sequence variants within DREs.

INDIVIDUAL NON-CODING IBD VARIANTS ALTER DNA REGULATORY FUNCTIONS

As the vast majority of associated SNPs lies in non-coding DNA, much effort has gone into identifying candidate genes by linking specific variants to genomic regulatory functions. Delineating individual loci has led to the identification of pathogenic regulatory mechanisms and the genes that are affected by non-coding variants.

IRG locus
The association of the IRGM gene locus to IBD has been established through multiple GWAS.69–71 IRGM is of great interest as it is involved in the early phases of autophagy, a process implicated in IBD pathogenesis.69 72 Indepth sequencing of the coding sequence of this gene could not reveal any non-synonymous mutations.69 This implies that the causal variant must be located in non-coding sequences. Indeed, a common 20 kb deletion polymorphism and two small insertions were found upstream of the IRGM gene body and turned out to be in strong linkage disequilibrium (LD) with the most strongly CD-associated SNP. Subsequently, the effect of the deletion and insertions was studied.69 71 The risk alleles were found to perturb IRGM expression levels, and subsequently manipulated IRGM expression affected cellular autophagy.71 Finally, a family of miRNAs are involved in the regulation of IRGM expression and were found to downregulate the protective allele, but not the risk allele.73

PTGER4 locus
A GWAS by Libioulle et al identified a novel IBD-risk locus on chromosome 5p13.1. The associated risk variants map to a 1.25 Mb gene desert, which complicated candidate gene identification. To test the regulatory potential of the locus, the effect of the SNPs on expression levels of the neighbouring genes...
Recent advances in basic science

Figure 3  Candidate gene approaches for disease-associated variants. (A) In genome-wide association studies, sequence variants at multiple genomic loci are studied. In this example, studying sequence variants at an IBD-associated locus reveals a C-allele was found more frequently in the patient population; therefore, this allele is determined to be a disease-associated variant. (B) Model of classical candidate gene approaches. A disease-associated variant is considered to be a marker for a causative coding variant in a gene that is transmitted to offspring on the same stretch of DNA, that is, inherited on the same haploblock. This gene is considered to be a possible candidate gene. For example, the IBD-associated SNP rs630923 (A/C) is located in the vicinity of CXCR5. CXCR5 is therefore considered to be an IBD candidate gene. (C) Novel model of candidate gene approaches. In this model, the disease-associated variant lies within a DNA regulating element. The SNP in this element results in changes in the expression of the target gene. The target gene can be located outside the haploblock and will therefore not be found by using the classical model. For example, the IBD-associated SNP rs630923 is located in an enhancer that was found to regulate the IL10RA gene that is found in another haploblock. Therefore, IL10RA is considered as a candidate gene as well.

was profiled. This approach revealed two SNPs that significantly increase the expression of PTGER4. In silico analysis showed that this is likely caused by the alteration of two TFBS (NFKB and XBP1 [X-box binding protein 1], respectively). The increased affinity of these TFs for the associated locus could explain the increased expression of PTGER4. The role of this locus is supported by the increased susceptibility of Ptger4 mutant mice to dextran sulfate sodium (DSS)-induced colitis and the established roles of NFKB and XBP1 in IBD pathogenesis. Furthermore, variants at the associated locus were systematically screened for aberrant regulatory capacity in lymphoblastoid cells. This revealed a single SNP in a distal enhancer that affects the expression of PTGER4 in vitro and could be rescued by genome editing with CRISPR/Cas9.

TRIB1 locus

There are two SNPs associated with CD that are located upstream of the coding sequence are found at open and therefore likely active chromatin. These two SNPs were found to alter T-Bet binding motifs and result in reduced T-bet binding in vivo. This is relevant because T-Bet is a TF that is involved in T cell differentiation and plays a key role in T cell-mediated colitis. Furthermore, a direct link between T-bet and TRIB1 was established by showing that T-Bet−/− mice show decreased TRIB1 expression. These data show that these CD-associated SNPs alter transcription regulatory processes that correlate with TRIB1 expression.

IL18RAP locus

In a GWAS from 2010 an IBD-associated variant on chromosome 2q12 was identified. This variant was studied through mRNA profiling in whole blood samples. This revealed that the minor allele specifically correlated with altered expression of the IL18RAP gene. Other associated SNPs at the same locus were found to alter the T-bet TFBS that results in differential expression of IL18RAP.

TPL2 locus

TPL2 (MAP3K8) maps to a locus that is associated to CD. Although no variants that caused amino acid changes were found, TPL2 was an obvious IBD candidate gene because it is an important player in T cell and innate responses, and it induces cytokine production in a pattern recognition receptors-signalling
Figure 4  Candidate gene identification through eQTLs and 4C. (A) Identification of candidate genes based on the proximity of a gene to the enhancer that carries the IBD variant is a biased approach. From the linear composition of DNA, it is not possible to identify the genes that are regulated by associated enhancers. (B) eQTLs are used to identify differential expression between alleles that carry different IBD-associated variants. The differentially expressed genes are considered to be candidate genes. (C) 4C is used to study the 3-dimensional conformation of the chromatin and identify candidate genes based on their physical interaction with IBD-associated enhancers. 4C, circular chromatin conformation capture; eQTLs, expression quantitative trait loci.

The studies described above concern examples of the association of single IBD-associated loci with a putative DNA regulatory function. However, there is a strong need for novel approaches to systematically identify the genes that are regulated through elements that carry IBD variants (figure 4A).

IBD-associated variants overlap eQTLs and influence transcription levels

A common feature of regulatory elements is their influence on RNA expression. Therefore, SNPs that contribute to a disease phenotype are expected to affect allele-specific RNA expression levels. This mechanism is used to profile eQTLs (expression quantitative trait loci), that is, loci that contain sequence variants that influence the expression of specific genes, thereby identifying SNPs that are linked to transcription regulation (figure 4B). As regulatory activity is cell type-specific, the influence of sequence variants is limited to cells in which the overlapping DRE is active. Therefore, eQTL databases of many cell types have been developed. eQTL profiles of cell types that are likely involved in the IBD pathogenesis are used to assign candidate genes to IBD-associated SNPs that influence expression levels. This approach is now commonly used to complement candidate gene approaches that are based on genic distances between SNPs and genes. Using eQTLs and regulatory information enables the identification of candidate genes for many loci that could not have been done previously. This is exemplified by a GWAS in which only 3 of 38 novel SNPs were in LD with known missense mutations, whereas 14 SNPs showed eQTL effects. Besides allele-specific influence on RNA expression, SNPs can also influence chromatin landscapes and TF binding. IBD-associated SNPs were found to influence the accessibility of the DNA and thereby likely influence the extent to which DREs can execute their function in individuals that carry risk variants. Furthermore, IBD-associated SNPs were found to be enriched for localisation to TFBS and to result in allele-specific affinity of TFs. Finally, DNA methylation that influences DNA accessibility was confirmed to show allele-specific
patterns. As such, various layers and mechanisms have been discovered that enable a better understanding of the complex role that genetic variants can play, ultimately through (defected) regulation of DNA transcription of relevant IBD-related genes.

Candidate genes physically interact with DNA regulatory regions

Many studies specifically analyse whether associated SNPs affect the expression of genes that are located in the vicinity of the SNP. To overcome this biased approach for the identification of candidate genes, we developed a novel, unbiased method that complements classical approaches to candidate gene identification (figure 4C). This approach relies on the physical interaction between enhancer elements and the genes they regulate. Using 4C-seq (circular chromatin conformation capture sequencing), we studied each gene that interacts with one of the 92 active enhancer elements that carry an IBD-associated SNP. We applied this technique to intestinal epithelial cells (IECs), monocytes and lymphocytes and identified 902 putative candidate genes with an average distance of 300 kilo base pairs per interaction. These results emphasise that genes that contribute to the IBD pathogenesis can be located further from the associated SNP than is assumed in classical candidate gene approaches and has recently been applied to other complex genetic diseases. This approach identified noteworthy genes including ATG9A, a gene involved in autophagy that has been implicated in IBD pathogenesis, and IL10RA, a gene that has been shown to play a role in monogenic forms of IBD.

Gene prioritisation

With increasing knowledge on the regulatory functions of the majority of IBD-associated loci, the complexity of the genetic background of IBD seems to be ever expanding. Therefore, in silico methods are being developed that integrate all regulatory, chromatin, coding and non-coding information to identify the key regulators in IBD. Peters et al applied a predictive model to identify gene networks that play a role in IBD and subsequently validated 12 key drivers of IBD pathogenesis. Our approach, through systematic analysis of chromatin interactions, helped identify common upstream regulators of the IBD candidate genes. As such, our results suggest an important role for HNF4A (a TF that belongs to the nuclear hormone receptor super-family) in both intestinal epithelium and immune cells. These in silico approaches are crucial to translate the extending number of IBD-associated genes to key regulators of the main pathogenic pathways and finally to identify novel therapeutic targets.

REGULATORY INFORMATION CREATES NOVEL INSIGHT IN CELL TYPES AND DISEASE STATES

On the one hand, the cell type specificity of DRE activity can complicate the studies of genetic variants in regulatory elements, as the functional background of each associated SNP may be present only in specific cells. Reciprocally, this phenomenon can help us to pinpoint cell types that are involved in IBD pathogenesis as the active regulatory elements from these cells are enriched for IBD-associated variants. Therefore, a characteristic of DRE that seemed complicating at first has paved the way for the identification of cell types that play a role in the IBD pathogenesis. The first study to apply this strategy showed that T helper 17 and T helper 1 cells have the highest accumulation of SNPs in accessible chromatin. Studying the enrichment of IBD-associated SNPs in cell type-specific active DRE revealed marked differences between UC and CD.

We and others have shown that in UC both IECs and immune cells seem to be important players, whereas in CD IECs are found to play a less important role than immune cells. This implies that there are distinct pathological processes underlying CD and UC and that these are limited to immune cells in CD, although in UC the intestinal tissue itself is a major player.

DREs are differentially active among cell types and among cell states. Studying the activation of monocytes through stimulation with lipopolysaccharides (LPS) or interferon gamma (IFNγ) revealed many context-specific eQTLs. This means that some SNPs will only affect pathogenicity on, for example, inflammation or during infection. These context-specific eQTLs are now used in search of causative genes in GWAS. A recent study has identified eQTLs in ileal biopsies from patients in different stages of CD (healthy, complication-free disease and disease progression with stricturing or penetrating disease). Through this approach, disease stage-specific eQTLs have been identified. The IBD-associated SNPs that form these eQTLs are therefore likely stage-specific and may be used to predict disease progression.

DREs as therapeutic targets

The majority of IBD-associated SNPs have been shown to affect transcription regulation by altering the sequence of DRE. This creates possibilities for novel therapeutic strategies. Based on the common features of the SNPs that are involved in DNA regulation, druggable targets may be defined.

The presence of SNP in a disease-associated locus can result in changes in TFBS and in the chromatin landscape. Although there is an interplay between the deposition of histone modifications and the affinity of transcription factors for TFBS, they can be targeted through different mechanisms. Here we will discuss how the chromatin landscape and key IBD TFs can be targeted and we will review the progress that has been made on this score.

Targeting the chromatin landscape

The activity of DREs strongly correlates with the co-occurrence of histone modifications, DNA methylation and TF binding. Histone modifications are covalent post-translational modifications of one of the four histone tails including acetylation and methylation (figure 5). The tails of histones H3 and H4 are important for transcriptional regulation of numerous genes. Modifications of histones by acetylation are known to weaken the chemical attractions between nucleosome components, enabling the DNA to uncoil from nucleosomes and allowing access to proteins important for transcription, such as RNA polymerase II and TFs. Acetylation of histones by ‘writer’ enzymes called acetyltransferases is known to increase the expression of the genes that are regulated by the acetylated enhancers. The addition of a methyl group is mediated by the writer enzyme called histone methyltransferases (HMT). This enzyme can either activate or further repress transcription, depending on the histone tail, and subsequently the amino acid that is being methylated and the presence of other methyl or acetyl groups in the vicinity. Acetyl and methyl groups can be removed by ‘eraser’ enzymes called histone deacetylases (HDACs) and histone demethylases, respectively. Moreover, ‘reader’ enzymes such as bromodomains can recognise histone modifications and direct a specific transcriptional outcome by modifying chromatin structure or recruiting machinery involved in gene expression. Due to their influence on chromatin structure and transcription, drugs targeting
enzymes capable of adding (writers), removing (erasers) and recognising (readers) major enhancer-associated histone modifications could be a promising therapy for reversing aberrant DRE activity seen in the context of disease. One such histone modification which has shown great promise in the treatment of IBD is histone acetylation. Table 1 presents the available compounds with clinical potential.

HDAC inhibitors
The first potential targets are HDACs. Studies in both murine and human immune cells and colonic mucosa have shown that a lack of DRE acetylation of immune genes is involved in the pathogenesis of IBD. Inhibitors of HDACs increase the levels of acetylation, and administration to mice resulted in the amelioration of colitis, a reduction of proinflammatory cytokines and a decrease of migratory inflammatory cells in the colonic mucosa. There are 11 isoforms of HDACs, each of which can be inhibited by specific compounds (Table 1). HDAC inhibitors have shown to have multiple substrates that are not limited to HDACs. The effect of HDAC inhibitors can therefore not be automatically and solely ascribed to their effect on the chromatin landscape.

Here, we will review HDAC inhibitors that affect the chromatin landscape and subsequently result in a putative beneficial effect in IBD. Many of these inhibitors are already being used in the clinic, mainly as anticancer treatment. One HDAC inhibitor, the short-chain fatty acid butyrate, is already used as treatment for IBD. The putative mechanism is inhibition of HDAC9, which enhances histone H3 acetylation in the promoter region of NOD2. In both an in vitro study on human IECs and in in vivo murine models of experimental colitis, this drug increased Nod2 expression that was associated with reduced nuclear TF NFκB signalling, reduction of inflammation and improved integrity of the intestinal epithelium. The effect of butyrate on IEC proliferation was shown to be due to its effect on HDAC activity and independent of its potential to target G protein-coupled receptors.

Suberoylanilide hydroxamic acid and valproic acid are HDAC inhibitors that have passed to advanced clinical stages for anticancer treatment. These inhibitors cause a dose-dependent increase in H3 acetylation at the site of inflammation and are associated with macroscopic and histological reduction of disease severity, as well as marked suppression in
Recent advances in basic science

Table 1 Therapeutics that target chromatin landscape and key regulators: overview of putative and novel therapeutics for IBD based on their potential to target chromatin modifiers or key regulators

| Putative effect in IBD | Compound                                                                 | Target                      | IBD-related preclinical studies | Clinical trials (phase) |
|------------------------|---------------------------------------------------------------------------|-----------------------------|---------------------------------|-------------------------|
| HDAC inhibitors        | Promote acetylation in DRES leading to increased transcription of genes in murine and human immune cells and colonic mucosa associated with reduction of disease severity and inflammation. | Sodium butyrate             | Isomorf 1–5, 7–9\(^{14}\) Human,\(^{14}\) mouse\(^{107}\)–\(^{146}\) | UC (NCT01282905), shigellosis (II) |
|                        | Valproic acid                                                            | Isomorf 1–3, 8\(^{14}\) Human,\(^{111}\) mouse\(^{107}\) | Solid tumours (II), Alzheimer's disease (II), AD (II), schizophrenia (III), glycogen storage disease type V (II), SMA (II), supranuclear palsy (II), bipolar disorder (III), HIV (II), leukaemia (II) |
|                        | Tacrolimus                                                               | Isomorf 1–3\(^{14}\) Human\(^{14}\) | MM(II), solid tumours (III), MDS (II) |
|                        | Quinostatin                                                              | Isomorf 1–11\(^{15}\) Human\(^{15}\) | Leukaemia (II), MM (II), lymphoma (I), solid tumours (II) |
|                        | Trichostatin A                                                           | Isomorf 1, 3, 4, 6, 10 Mouse\(^{117}\)–\(^{119}\) | – |
|                        | Varnoratin/suberoylanilide hydroxamic acid                               | Isomorf 1–11\(^{15}\) Human, mouse\(^{108}\)–\(^{110}\) | – |
|                        | Givinostat                                                               | Isomorf 1–10 Mouse\(^{114}\)–\(^{117}\) | Leukaemia (II), MM (II), CTCL (II), systemic juvenile idiopathic arthritis (II), polyglucosyamines vera (II) |
|                        | Entinostat                                                               | Isomorf 1–3, 9\(^{14}\) Human,\(^{111}\) mouse\(^{107}\) | Leukaemia (II), solid tumours (II) |
|                        | Panobinostat                                                             | Isomorf 1–11\(^{15}\) Human,\(^{114}\) mouse\(^{107}\) | HIV(II), AML(II), lymphoma (II), MM (II), leukaemia (II), CTCL (II), solid tumours (II) |
|                        | Resminostat                                                              | Isomorf 1, 3, 6, 8\(^{15}\) – | Leukaemia (II), solid tumours (II) |
|                        | Mozolostat                                                               | Isomorf 1–5, 9–11\(^{14}\) Guinea pig\(^{112}\) human\(^{112}\) | MDS (II), leukaemia (II), lymphoma (II), solid tumours (II) |
|                        | Abexinostat                                                              | Isomorf 1–3, 6, 10\(^{14}\) Human\(^{116}\) | – |
|                        | Pracinostat                                                              | Isomorf 1–4, 7–11\(^{15}\) Human\(^{115}\) | MDS (II), myeloproliferative disease (II), leukaemia (II), solid tumours (II) |
|                        | Belinostat                                                               | Isomorf 1–4, 6–9\(^{14}\) Human\(^{116}\) | – |
|                        | Tubastatin A                                                             | Isomorf 6\(^{116}\) human\(^{116}\) | – |
|                        | Tabacin                                                                  | Isomorf 6\(^{116}\) Mouse\(^{116}\) | – |
|                        | Santacruzamate-A                                                         | Isomorf 2, 4, 6\(^{116}\) Human\(^{116}\) | – |
|                        | Romidepsin                                                               | Isomorf 1, 2\(^{115}\) Human\(^{115}\) | – |
|                        | Abexinostat                                                              | Isomorf 2, 3, 6, 10 Human\(^{116}\) | Leukaemia (II), MM (II), lymphoma (II), solid tumours (II) |
|                        | CUDC-101                                                                 | Isomorf 1–10 – | Solid tumours (I) |
| BET inhibitors          | Preferential inhibition of inflammation-associated gene expression involved in proinflammatory activity of murine and mouse monocyte, macrophages and T lymphocytes. | JQ1 BET                     | Human,\(^{110}\)–\(^{116}\) mouse\(^{107}\)–\(^{110}\) | None |
|                        | I-BET762                                                                 | BET Mouse\(^{117}\) | Solid tumours (II) |
|                        | I-BET115                                                                 | BET Mouse\(^{117}\) | – |
|                        | ZEN3694                                                                  | BET – | Solid tumours (II) |
|                        | INCB054329                                                               | BET – | Solid tumours and haematological malignancies (II) |
|                        | BMS-996158                                                               | BET – | Solid tumours (II) |
|                        | FT-1701                                                                  | BET – | Leukaemia (II), MDS (II), lymphoma (II) |
|                        | RDB870810/TEN-010                                                        | BET – | MM (II), leukaemia (II), MDS (II), solid tumours (II) |
|                        | RVX002022                                                                | BET Human\(^{116}\) | Diabetes mellitus type 2 (III), cardiovascular disease (III), Fabry disease (II), chronic kidney failure (II), glioblastoma multiforme (II), solid tumours (II) |
|                        | CPI-0610                                                                 | BET – | MM (II), lymphoma (II), myelodysplasia (II), solid tumours (II) |
|                        | OT-015/MK-8628                                                           | BET – | MDS (II), lymphoma (II), solid tumours (II) |
| Methytransferase inhibitors | Upregulation of FOXD3 to increase EZH2 expression. | Decitabine (5-aza-2'-deoxycytidine or 5-aza-dC) DNA methyltransferase Human\(^{116}\) | – |
|                        | Tazemetostat                                                             | EZH2 Mouse\(^{117}\) | – |
|                        | SHH2554                                                                  | EZH2 – | – |
|                        | CPI-1205                                                                 | EZH2 Human\(^{116}\) | Leukaemia (II), solid tumours (II) |
| Key regulator modulators | NFKB inhibition. | Dehydroxymethylpseudouracilinomin | NFKB (nuclear translocation) Mouse\(^{116}\) | – |
|                        | Cumarin                                                                  | NFKB Mouse\(^{116}\) | – |
|                        | NFKB decay oligonucleotide                                               | NFKB Rat\(^{116}\) | Atoxic dermatitis (II) |
|                        | HNF4x agonists show protective effect.                                   | C14-C18 fatty acids HNF4A Crystal structure\(^{115}\)–\(^{116}\) | – |
|                        | Inhibition of the JAK/STAT pathway.                                      | Tofacitinib JAK1, JAK2, JAK3, TYK2 Human\(^{116}\) | Crohn's disease (II)\(^{116}\) and UC (III),\(^{116}\) immune-related diseases (III) |
|                        | Peficitinib                                                               | JAK1, JAK3 Human\(^{116}\) | UC (II),\(^{116}\) rheumatoid arthritis (III) |
|                        | Upadacitinib                                                             | JAK1 Human\(^{116}\) | Crohn's disease (II) (NCT02365649) |
|                        | Filgotinib                                                               | JAK1 Human\(^{116}\) | Crohn's disease (II),\(^{116}\) immune-related diseases (II) |
proinflammatory cytokine expression in the colon.\textsuperscript{100, 109} This anti-inflammatory effect could be explained by HDAC inhibition in dendritic cells that results in decreased expression of inflammatory cytokines.\textsuperscript{110, 111} Furthermore, the HDAC inhibitor givinostat is being studied in clinical trials for systemic-onset juvenile idiopathic arthritis and has obtained a good safety profile.\textsuperscript{112, 113}

KAT2B is a lysine acetyltransferase that is downregulated in inflamed colonic tissue of patients with CD and UC. Inhibition of KAT2B by anacardic acid demonstrated reduced levels of histone H4 lysine 5 acetylation (H4K5ac) in the interleukin-10 (IL-10) promoter region which was associated with a dose-dependent decrease in the expression of IL-10.\textsuperscript{99} HDAC1-selective inhibitors such as tacedinaline and quisinostat promote H4K5 acetylation and restore IL-10 transcription.\textsuperscript{99} The reduction of IL-10 has been linked to IBD as patients with deleterious mutations in IL-10, IL10RA and IL10RB suffer from severe infantile-onset IBD.\textsuperscript{114}

Overall, many studies have demonstrated that these small molecules can target important pathways in the pathogenesis of IBD, and their efficacy is currently being studied in clinical trials.

**BET inhibitors**

BET (bromodomain and extraterminal) proteins are ‘reader’ proteins which recognise acetylated lysine residues on regulatory elements and influence expression by recruiting TFs and chromatin remodelling factors such as the SWItch/Sucrose Non-Fermentable (SWI/SNF) complex.\textsuperscript{115} BET proteins can be specifically found at super-enhancers that are characterised by extensive acetylation of histone H3 at lysine 27 and increased binding TFs. Super-enhancers are highly cell type-specific and cell state-specific and might therefore be a target in disease-specific processes.\textsuperscript{116-119} After all, both healthy controls and patients with IBD may contain the same SNPs in an enhancer, but the enhancer may only be active due to tissue or cell context-like inflammation and the presence of cytokines. Therefore, the enhancers that only become active in certain contexts are more likely to have an influence on the pathogenesis of a disease, and thus it is beneficial that BET inhibitors are studied in the context of inflammatory disease. There is evidence that inhibiting BET proteins leads to a reduction in inflammation-associated gene expression and can modulate the proinflammatory activity of adaptive immune cells.\textsuperscript{120} For example, the BET inhibitors JQ1, I-BET762 and I-BET151 were shown to reduce the production of proinflammatory cytokines in monocytes and macrophages stimulated by LPS in vitro and in mice.\textsuperscript{120} Studies on human inflamed joint synovial fluid show that treatment with JQ1 on CD4+ memory/effector T cells preferentially inhibited the expression of genes involved in proinflammatory and cytokine-related processes regulated by super-enhancers.\textsuperscript{121} Although BET inhibitors have not been studied in the context of IBD, their immune-modulating potential points to promising effects for IBD treatment.

**MT inhibitors**

The methyltransferase EZH2 (enhancer of zeste homolog 2) is an important player in IBD. Patients show significantly reduced expression, and it has been shown in mice that inhibition of EZH2 leads to increased immune responsiveness that is associated with an increased sensitivity to DSS-induced and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced experimental colitis.\textsuperscript{122} In addition, mice that lack EZH2 specifically in regulatory T cells (Tregs) develop spontaneous IBD. EZH2 functions as a cofactor of FOXP3 for the regulation of Treg-specific gene networks. As dysregulation of EZH2 plays a role in the development of IBD in both mice and humans, treatment that restores HMT activity in Tregs could be beneficial for treating IBD.\textsuperscript{122}

**Targeting key regulators**

Inflammatory pathways that play a role in the pathogenesis of IBD can be targeted through cytokine inhibitors. This way, the cascade that results from cytokine-receptor binding can be blocked, after which inflammation is dampened. Several monoclonal antibodies have been developed and have become common therapeutics used in IBD. The majority of clinically approved antibodies target tumour necrosis factor α, a cytokine that can be produced by many cell types and is found to be upregulated in IBD.\textsuperscript{123} Other cytokines including IFNγ, IL-6, transforming growth factor beta (TGFβ) and IL-12/p40 are being studied as therapeutic targets in IBD with varying degrees of success.\textsuperscript{124, 125} However, these targets may not completely represent the common pathways that have been identified through integrating genetic and epigenetic data.

As described above, recently, many attempts have been done to identify key regulators in the pathogenesis of IBD. The goal of these approaches is to identify single players preferably affecting multiple IBD genes at the same time.\textsuperscript{87, 92} Many of these key regulators turn out to be TFs. This can be explained by both the many associated loci that contain the same binding motifs for a limited number of TFs and by the involvement of pathways that are regulated by a limited number of TFs. Alterations in TF activity therefore can play a central role in the IBD pathogenesis, and targeting these factors seems a valid approach. However, TFs have proved to be challenging targets and have often been termed ‘undruggable’.\textsuperscript{97} Nevertheless, several strategies for TF targeting are being developed (table 1).

**HNF4A**

We and others have identified HNF4A as an important key regulator in IBD that interferes with pathways in multiple relevant cell types.\textsuperscript{87, 92} HNF4A provides an interesting target, as there are multiple levels in which HNF4A contributes to IBD: enrichment of IBD-SNPs in HNF4A binding sites, altered DNA binding,\textsuperscript{89} regulation of expression of IBD candidate genes\textsuperscript{87, 92} and differential expression of HNF4A itself. Notably, Hnf4a knockout mice are prone to develop DSS-induced colitis.\textsuperscript{126} There are currently no HNF4A agonists ready to be tested in clinical studies. Conversely, multiple HNF4A inhibitors are used in vitro.\textsuperscript{127} However, HNF4A seems to have a protective effect in IBD; therefore, agonists rather than antagonists are of interest as putative therapeutic compounds. Identification of HNF4A agonists has proven difficult and there are currently no compounds available that upregulate HNF4A. Nevertheless, studies on the in vivo ligands of HNF4A reveal that medium-chain and long-chain fatty acids are the natural ligands and activators of HNF4A.\textsuperscript{128-130}

**NFKB**

As for agonists of HNF4A, finding specific antagonists for another IBD key regulator, NFKB, has been a challenge. For NFKB, an alternative TF targeting approach has shown success in this context. By using decoy oligonucleotides, NFKB-DNA binding is decreased through competitive inhibition. Decoy oligonucleotides are short, double-stranded DNA molecules containing the binding motif of a specific TF. When TFs bind to decoy oligonucleotides, their availability for binding to DREs decreases. A major limitation of this technique is that decoy
oligonucleotides are easily degraded by nucleases. However, recent developments have increased their stability and made them more nuclease-resistant. Administration of an NFKB decoy oligonucleotide in rats limited the expression of pro-inflammatory pathways and showed increased survival rate on inducing DSS-induced colitis.\textsuperscript{131} Another NFKB inhibitor, dehydroxyleptopenyquinomicin, blocks the nuclear translocation of NFKB and ameliorated experimental TNBS-induced and DSS-induced colitis in mice.\textsuperscript{132} Finally, the natural NFKB inhibitor curcumin has shown positive effects on the treatment of IBD in phase I, II and III trials.\textsuperscript{133}

STAT3

STAT3 is a key TF in the pathogenesis of IBD. The nuclear translocation of STAT3 is mediated by Janus kinase (JAK).\textsuperscript{134} Therefore, inhibition of JAKs subsequently leads to the inhibition of STAT3 and thereby of the downstream JAK/STAT pathway. On the discovery of a role of STAT3 in IBD pathogenesis, JAK inhibitors have been developed and tested in clinical trials. To date, such drugs have not been proven efficacious in CD.\textsuperscript{135,136} However, JAK inhibitors are currently used for the treatment of UC.\textsuperscript{137,138}

CONCLUSION AND DISCUSSION

Although GWAS of IBD have revealed many associated sequence variants and some involved genes, these findings only explain a minor portion of the genetic background of IBD.\textsuperscript{8,19} Therefore, new insights into the genetic make-up of these complex genetic diseases are needed. We have reviewed the accumulating evidence regarding the contribution of sequence variants in DREs to the pathogenesis of IBD. This contribution is supported by many studies, and steps are being taken to translate these findings into new diagnostic, preventive and therapeutic measures.

Studying genetic variants in regulatory elements and their effect on the pathogenesis of complex genetic diseases remains challenging. The context-specific activity of DRE makes their identification and annotation of DRE difficult. The limited effect of SNPs in DRE compared with the effect of variants that alter gene coding sequences further complicates the identification of pathogenic regulatory variants. Over the last years, multiple high-throughput techniques have been developed that enable the efficient annotation of DRE and the evaluation of allele-specific effects. These techniques are built on epigenetic signatures, chromosome conformation, genome editing and self-transcribing activity of regulatory elements and have been thoroughly reviewed by Elkon and Agami.\textsuperscript{139} To assay the effects of genetic variants on the activity of regulatory region, the cell type-specific activity of enhancers needs to be taken into account as the phenotype that is caused by an SNP might only be present in a limited number of cell types. Assaying an SNP in the wrong cell type or developmental stage will not reveal a deleterious effect. This is further complicated by the finding that the phenotype of some genetic variants is dependent on the cell state (eg, activated cells vs non-activated cells).\textsuperscript{140} Similar to eQTL studies, the cell type, developmental stage and cell state-dependent effect of SNPs on DRE causes a high chance of false-negative detection. To increase detection of disease-associated SNPs, assays should be performed in a multitude of cell types and conditions. To address this, eQTL databases that contain a plethora of cell types and developmental stages are now being developed.\textsuperscript{140}

New therapeutic measures for IBD include targeting histone writers, readers and erasers, as well as key regulators of IBD networks. A possible drawback of targeting histone modifications and key regulators is that the effect of the compounds will not be limited to the tissues that are affected by the disease. However, the predictive value of IBD-associated SNPs on the pathogenic cell types can be a lead to develop therapeutics that can be delivered to specific cells. This may be associated with adverse effects as is seen for many therapeutics that target general processes, including immune modulators and chemotherapeutics. The extent of the adverse effects and the efficacy of these putative new compounds are currently being studied in clinical trials. Although most trials concern malignant diseases, the outcome of the trials can be highly relevant for IBD (as for safety, dose ranging and side effects). In table 1 we reviewed multiple compounds that have shown to be effective in vitro and in vivo and are already being used in human diseases.

We believe that recent insights into the roles of DRE in IBD will result in the development of novel therapeutic strategies. With novel techniques like CRISPR/Cas9, which are now widely used for scientific purposes, genetic diseases may eventually be treated by restoring genetic defects. Although we reviewed the contribution of genetic variants to the pathogenesis of IBD, we have not discussed the therapeutic potential of genome editing. As patients carry multiple SNPs that contribute to the pathogenesis of IBD, treatment of patients by targeting these common variants through genome editing does not seem an efficient approach, even more so because the loci but not the disease-causing variants have been identified. However, profiling the disease-associated SNPs in individual patients could be useful in predicting response to therapeutics and thereby in defining a personalised therapeutic strategy. We therefore suggest including SNP profiles in the analyses of clinical trials to establish the variants that are predictive for treatment outcome.\textsuperscript{141,142}

In this review, we have shown that sequence variants in DREs are involved in the pathogenesis of IBD. The majority of IBD-associated sequence variants colocalise with active DREs, and the mechanisms through which these SNPs lead to pathogenic processes have been intensively studied over the last decade. This resulted in the identification of novel therapeutic targets including regulatory layers such as the chromatin landscape and key regulatory TFs.

Acknowledgements We want to thank Jorg van Loosdregt for reading the manuscript and providing valuable comments.

Contributors CAM performed the literature search and was involved in writing the manuscript. ACJvdL performed the literature search and was involved in writing and editing the manuscript. MM supervised the project and was involved in writing and editing the manuscript.

Funding This work was supported by the Alexandre Suerman Stipendium (2014) through CAM and WKZ Funds (2012) through MM.

Competing interests None declared.

Patient consent Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Ruuska T, Vajjalaiti P, Arjäniö P, et al. Prospective evaluation of upper gastrointestinal mucosal lesions in children with ulcerative colitis and Crohn's disease. J Pediatr Gastroenterol Nutr 1994;19:181–6.
2. Halme I, Faavola-Sakkı P, Turunen U, et al. Family and twin studies in inflammatory bowel disease. World J Gastroenterol 2006;12:3668–72.
et al. Concordance of inflammatory bowel disease among Danish twins. results of a nationwide study. Scand J Gastroenterol 2000;35:1075–81.

3 Thompson NP, Dtscholl R, Pounder RE, et al. Genetics versus environment in inflammatory bowel disease: results of a British twin study. BMJ 1996;312:95–6.

4 Tyler AD, Milgrom R, Stempak JM, et al. The NOD2/Nramp polymorphism is associated with worst outcome following frail pouch-ana1 anastomosis for ulcerative colitis. Gut 2013;62:1433–9.

5 Jostins L, Ripke S, Weiriska RM, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119–24.

6 Frankie A, McGovern DF, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet 2010;42:1116–20.

7 Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43:246–2.

8 Siroux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007;39:970–80.

9 Libouille C, Louis E, Hansoul S, et al. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5q13.1 and modulates expression of PTGER4. PLoS Genet 2007;3:e58.

10 Liu JZ, von Sommerson S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet 2015;47:970–80.

11 Rivas MA, Beaudoin M, Gardet A, et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet 2011;43:1066–73.

12 de Lange KM, Moutsianas L, Lee JC, et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet 2013;45:526–31.

13 Huang H, Fang M, Jostins L, et al. Fine-mapping inflammatory bowel disease loci to single-variant resolution. Nature 2017;547:173–8.

14 Zheleva EK, von Diemen CC, Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 2009;10:43–55.

15 Mokry M, Moldendorf S, Wiegerink CL, et al. Many inflammatory bowel disease risk loci include regions that regulate gene expression in immune cells and the intestinal epithelium. Gut Microbiol 2014;16:1040–7.

16 Barrett JC, Hansoul S, Nicolaie DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet 2008;40:955–62.

17 Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461–3.

18 Hong SN, Park C, Palanisamy V, et al. Deep resequencing of 131 Crohn’s disease associated genes in pooled DNA confirmed three reported variants and identified eight novel variants. Gut 2016;65:788–96.

19 Bulger M, Groudine M. Functional and mechanistic diversity of distal transcription enhancers. Cell 2011;144:327–39.

20 Ensembl. Human assembly and gene annotation. https://www.ensembl.org/Homo_sapiens/Info/Annotation (Accessed 3rd Sep 2018).

21 Elgar G, Vavouri T. Tuning in to the signals: noncoding sequence conservation in human assembly and gene annotation. http://www.ensembl.org/Homo_sapiens/Info/Annotation (Accessed 3rd Sep 2018).

22 Khan A, Zhang X, dsSUPER: a database of super-enhancers in human and mouse genome. Nucleic Acids Res 2016;44:D164–D171.

23 Hnisz D, Abraham BJ, Lee TL, et al. Super-enhancers in the control of cell identity and disease. Cell 2013;153:934–47.

24 Creighton MP, Cheng AW, Wlestead GG, et al. Histoire CHK27ac separates active from poised enhancers and predicts developmental landscape. Proc Natl Acad Sci U S A 2010;107:21931–6.

25 Heintzman ND, Stuart RK, Hon G, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 2007;39:311–8.

26 Di Croce L, Hellin K. Transcriptional regulation by polycomb group proteins. Nat Struct Mol Biol 2013;20:1147–55.

27 Engelkamp J, Haines JE, Peretz EM, et al. Local regulation of gene expression by IncRNA promoters, transcription and splicing. Nature 2016;539:452–5.

28 Pekowska A, Benoukraf T, Zacarías-Cabezà J, et al. H3K4 tri-methylation provides an epigenetic signature of active enhancers. Embo J 2011;30:4198–210.

29 Cole LI, Martins AL, Danko CG, et al. Analysis of nascent RNA identifies a unified architecture of initiation regions at mammalian promoters and enhancers. Nat Genet 2014;46:1311–20.

30 Marsh MN. Genetic, major histocompatibility complex, and the small intestine. A molecular and immunobiological approach to the spectrum of gluten sensitivity (‘celiac sprue’). Gastroenterology 1992;102:330–54.

31 Kowalczyk MS, Hughes JR, Garrard D, et al. Intraepithelial enhancers act as alternative promoters. Mol Cell 2018;45:457–8.

32 Koziczy I, Nayak KM, Howell KL, et al. DNA methylation defines regional identity of human intestinal epithelial organoids and undergoes dynamic changes during development. Gut 2019;68.

33 Vahedi G, Takahashi H, Nakayama S, et al. STARS shape the active enhancer landscape of T cell populations. Cell 2012;151:981–93.

34 Sakabe NI, Savic D, Nobrega MA. Transcriptional enhancers in development and disease. Genome Biol 2012;13:238.

35 Spedale M, Geddes CA, Koster MJ, et al. Tight cooperation between Mot1p and NC2B in regulating genome-wide transcription, repression of transcription following heat shock induction and genetic interaction with SAGA. Nucleic Acids Res 2012;40:996–1008.

36 Bajic VB, Tan SL, Suzuki Y, et al. Promoter prediction analysis on the whole human genome. Nat Biotechnol 2005;23:63–70.

37 Heinztman ND, Hon GC, Hawkins RD, et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 2009;459:108–12.

38 Gläs J, Seiderer J, Czyma Z, et al. PTGER4 expression-modulating polymorphisms in the 5’-3.1 region predispose to Crohn’s disease and affect NF-kB and XBP1 binding sites. PLoS One 2012;7:e52873.

39 Panis J, Vermeire S, Lindsay JF, et al. Tofacitinib in patients with ulcerative colitis: health-related quality of life in phase 3 randomised controlled induction and maintenance studies. J Crohns Colitis 2018;12:145–56.

40 Mauroano MT, Humbert R, Nyres E, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 2012;337:1190–5.

41 Chiba H, Kukata Y, Kinouchi S, et al. Allele-specific DNA methylation of disease susceptibility genes in Japanese patients with inflammatory bowel disease. PLoS One 2018;13:e0194036.

42 Venham NT, Kennedy NA, Adams AT, et al. Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease. Nat Commun 2016;7:13507.

43 Howell KJ, Koziczy I, Nayak KM, et al. DNA methylation and transcription patterns in intestinal epithelial cells from pediatric patients with inflammatory bowel diseases differentiate disease subtypes and associate with outcome. Gastroenterology 2018;154:585–98.

44 Alasoo K, Rodrigues J, Mukhopadhyay S, et al. Shared genetic effects on chromatin and gene expression indicate a role for enhancer priming in immune response. Nat Genet 2018;50:424–31.

45 Itoh T, Pistoni M, Cludts K, et al. Allele-specific DNA methylation reinforces PEAR1 enhancer activity. Blood 2016;128:1003–12.

46 Zhang P, Xia JH, Zhu J, et al. High-throughput screening of prostate cancer risk loci by single nucleotide polymorphisms sequencing. Nat Commun 2018;9:2022.

47 Kiplinen H, Waszak SM, Gschwind AR, et al. Coordinated effects of sequence variation on DNA binding, chromatin structure, and transcription. Science 2013;342:744–7.

48 McVicker G, de Geijn B, Degner JF, et al. Identification of genetic variants that affect histone modifications in human cells. Science 2013;342:747–9.

49 Li V, de Geijn B, Raj A, et al. RNA splicing is a primary link between genetic variation and disease. Science 2016;352:600–4.

50 Schaefer JS, MicrocRNA: how many in inflammatory bowel disease? Curr Opin Gastroenterol 2016;32:258–66.

51 Zacharopoulou E, Gazouli M, Trovalou M, et al. The contribution of long non-coding RNAs in inflammatory bowel diseases. Dig Liver Dis 2017;49:1067–72.

52 Weedon MN, Cebolla I, Patch AM, et al. Recessive mutations in a distal PTF1A enhancer cause isolated pancreatic agenesis. Nat Genet 2014;46:61–4.
Recent advances in basic science

94 Raine T, Liu JZ, Anderson CA, et al. Generation of primary human intestinal T cell transplantome reveals differential expression at genetic risk loci for immunemediated disease. Gut 2015;64:250–9.

95 Pradeepa MM. Causal role of histone acetylators in enhancer function. Transcription 2017;8:40–7.

96 Peeters JGG, Vasten SJ, van Wijk F, et al. Review: enhancers in autoimmune arthritis: implications and therapeutic potential. Arthritis Rheumatol 2017;69:1925–36.

97 Johnston SJ, Carroll JS. Transcription factors and chromatin proteins as therapeutic targets in cancer. Biochim Biophys Acta 2015;1855:183–92.

98 Gillette TG, Hill JA. Readers, writers, and erasers: chromatin as the whiteboard of heart disease. Circ Res 2015;116:1245–53.

99 Bai AH, Wu WK, Xu J, et al. DS-regulated lysine acetyltransferase 2B promotes inflammatory bowel disease pathogenesis through transcriptional repression of interleukin-10. J Crohns Colitis 2016;10:726–34.

100 Glauben R, Batra A, Fedde I, et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 2006;176:5015–22.

101 Ventham NT, Kennedy NA, Nimmor ER, et al. Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics. Gastroenterology 2013;145:293–308.

102 Markozavits D, Pichugin A, Barat A, et al. Histone deacetylase inhibitor abexinostat affects chromatin organization and gene transcription in normal B cells and in mantle cell lymphoma. Gene 2016;580:134–43.

103 Solomon JM, Pasupuleti R, Xu L, et al. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol 2006;26:28–38.

104 Holtzman L, Gersbach CA. Editing the genome: reshaping the genomic landscape. Annu Rev Genomics Hum Genet 2018;19:43–71.

105 Frieke J, Peric Z, Brissett E, et al. Impact of HDAC inhibitors on dendritic cell functions. Exp Hematol 2012;40:783–91.

106 Lee C, Kim BG, Kim JH, et al. Sodium butyrate inhibits the NF-kappa B signaling pathway and histone deacetylation, and attenuates experimental colitis in an IL-10 deficient mouse. Int Immunopharmacol 2017;51:17–46.

107 Simeoli R, Mattace Raso G, Pirzio C, et al. An orally administered butyrate-releasing derivative reduces neutrophil recruitment and inflammation in dextran sulphate sodium-induced murine colitis. Br J Pharmacol 2017;174:1484–96.

108 Kaiko GE, Ryu SH, Krous OI, et al. The colonic crypt protects stem cells from microRNA-determined beta-catenin metabolic dependencies. Gastroenterology 2016;150:1672–80.

109 Ali MN, Choioujkouh N, Takagi H, et al. The HDAC inhibitor, SAHA, prevents colonic inflammation by suppressing pro-inflammatory cytokines and chemokines in DSS-induced colitis. Acta Histochim Cytochem 2018;51:33–40.

110 Reddy P, Sun Y, Toubal T, et al. Histone deacetylase inhibition modulates interleukin-2, 24–120 inflammatory-dependent functions and regulates experimental graft-versushost disease in mice. J Clin Invest 2008;118:2562–73.

111 Nencioni A, Beck J, Werth D, et al. Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin Cancer Res 2007;13:3933–41.

112 Vojnovic I, Damjanov N, D’Urzo C, et al. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthrits. Arthritis Rheum 2011;63:1452–8.

113 Felce C, Lewis A, Arzumay A, et al. Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases. Aliment Pharmacol Ther 2015;41:26–38.

114 Shouval DS, Konnikova L, Griffith AE, et al. Enhanced TH17 responses in patients with IL10 receptor deficiency and infantile-onset IBD. Inflamm Bowel Dis 2017;23:1950–61.

115 Brown JD, Lin CY, Duan Q, et al. NF-kB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol Cell 2014;56:219–31.

116 Sands BE, Sandborn WJ, Feagan BG, et al. Perifactor, an oral janus kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomised, phase 2 Study. J Crohns Colitis 2012;15:1158–69.

117 Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 2017;389:266–75.

118 Duan Q, McMahon S, Anand P, et al. BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure. Sci Transl Med 2017;9:eaah5084.

119 Gelato KA, Schöckel I, Klingebiel O, et al. Super-enhancers define a proliferative PEG-10 expressing melanoma subgroup sensitive to BET inhibition. Oncogene 2018;37:512–21.

120 Tough DF, Pinjha RK. Immune disease-associated variants in gene enhancers point to BET epigenetic mechanisms for therapeutic intervention. Epigenomics 2017;9:573–84.

121 Peeters JGG, Vervoort SJ, Tan SC, et al. Inhibition of super-enhancer activity in autoinflammatory site-derived cells reduces disease-associated gene expression. Cell Rep 2015;12:1956–96.

122 Sarmento OF, Sivenga PA, Xiong Y, et al. The role of the histone methytransferase Enhancer of Zeste Homolog 2 (EZH2) in the pathological mechanisms underlying Inflammatory Bowel Disease (IBD). J Biol Chem 2017;292:706–22.

Meddens CA et al. Gut 2019;68:928–941. doi:10.1136/gutjnl-2018-317516
123 Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. *Gastroenterology* 2004;126:1593–610.
124 Caprioli F, Caruso R, Sarrà M, et al. Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases. *Br J Pharmacol* 2012;165:820–8.
125 Sedda S, Marafini I, Dinallo V, et al. The TGF-β/bSmad System in IBD Pathogenesis. *Inflamm Bowel Dis* 2015;21:2921–5.
126 Ahn SH, Shah YM, Inoue J, et al. Hepatocyte nuclear factor 4α in the intestinal epithelial cells protects against inflammatory bowel disease. *Inflamm Bowel Dis* 2008;14:908–20.
127 Kiselyuk A, Lee SH, Farber-Katz S, et al. HNF4α antagonists discovered by a high-throughput screen for modulators of the human insulin promoter. *Chem Biol* 2012;19:806–18.
128 Dhe-Paganon S, Duda K, Iwamoto M, et al. Crystal structure of the HNF4 α ligand binding domain in complex with endogenous fatty acid ligand. *J Biol Chem* 2002;277:37973–6.
129 Wisely GB, Miller AB, Davis RG, et al. Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids. *Structure* 2002;10:1225–34.
130 McIntosh AL, Petretti KD, Motestelli HA, et al. Liver-type fatty acid binding protein interacts with hepatocyte nuclear factor 4α. *FEBS Lett* 2013;587:3787–91.
131 Ozaki K, Makino H, Aoki M, et al. Therapeutic effect of ribbon-type nuclear factor-κB decoy oligonucleotides in a rat model of inflammatory bowel disease. *Curr Gene Ther* 2012;12:484–92.
132 Furakoshi T, Yamashita K, Ichikawa N, et al. A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice. *J Crohns Colitis* 2012;6:215–25.
133 Vecchi Brumatti L, Marcuzzi A, Tricario PM, et al. Curcumin and inflammatory bowel disease: potential and limits of innovative treatments. *Molecules* 2014;19:21127–53.
134 Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. *Nat Rev Immunol* 2003;3:900–11.
135 Sandborn WJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease. *Clin Gastroenterol Hepatol* 2014;12:1485–93.
136 Panes J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of crohn’s disease: results of two phase iiib randomised placebo-controlled trials. *Gut* 2017;66:1049–59.
137 Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. *N Engl J Med* 2012;367:616–24.
138 Sandborn WJ, Xu C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2017;376:1723–36.
139 Elkorn R, Agami R. Characterization of noncoding regulatory DNA in the human genome. *Nat Biotechnol* 2017;35:732–46.
140 Lonsdale J. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 2013;45:580–5.
141 López-Hernández R, Marinelli V, Campillo JA, et al. Genetic polymorphisms of tumour necrosis factor alpha (TNF-α) promoter gene and response to TNF-α inhibitors in Spanish patients with inflammatory bowel disease. *J Immunogenet* 2014;41:63–8.
142 Lacruz-Guzmán D, Torres-Moreno D, Pedroso F, et al. Influence of polymorphisms and TNF and IL1β serum concentration on the inflammasome response in Crohn’s disease and ulcerative colitis. *Eur J Clin Pharmacol* 2013;69:431–8.
143 Davie JR. Inhibition of histone deacetylase activity by butyrate. *J Nutr* 2003;133:2485S–93.
144 Brogdon JL, Xu Y, Szabo SJ, et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. *Blood* 2007;109:1123–30.
145 Furusawa Y, Ohtani Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature* 2013;504:446–50.
146 Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature* 2013;504:451–5.

147 Zhou H, Cai Y, Liu D, et al. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21(WAF1/CIP1) and p19(INK4A) upregulation in hepatocellular carcinoma. *Cell Prog* 2018;51:e12447.
148 Méhul B, Perrin A, Grisendi K, et al. Mass spectrometry and digestway technology emphasize protein acetylation profile from quinsnostat-treated Hu7T8 CTLL cell line. *J Proteomics* 2018;187:126–42.
149 Jung IJ, Lee IS, Jeong YI, et al. Apicidin, the histone deacetylase inhibitor, suppresses Th1 polarization of murine bone marrow-derived dendritic cells. *Int Immunopathol Pharm* 2009;22:501–15.
150 Bode KA, Schroder K, Hume DA, et al. Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. *Immunology* 2007;122:596–606.
151 Glauben R, Sonnenberg E, Wetzl M, et al. Histone deacetylase modulators modulate interleukin 6-dependent CD4+ T cell polarization in vitro and in vivo. *J Immunopharmacol* 2014;389:612–41.
152 Song W, Tai YT, Tian Z, et al. HDAC inhibition by LBHS89 affects the phenotype and function of human myeloid dendritic cells. *Leukemia* 2011;25:161–8.
153 Assem sK, Pel KH, Wan BY, et al. Effects of a selection of histone deacetylases inhibitors on mast cell activation and airway and colonic smooth muscle contraction. *Int Immunopharmacol* 2008;8:1793–801.
154 Sikandar S, Dizon D, Shen X, et al. The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. *Oncotarget* 2010;1:596–605.
155 Park JM, Huang S, Tougeron D, et al. MSH3 mismatch repair protein increases sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells. *PLoS One* 2013;8:e66369.
156 Yong WP, Goh BC, Soo RA, et al. Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies. *Ann Oncol* 2011;22:2516–22.
157 Campbell GR, Bruckman RS, Chu YL, et al. Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1. *J Biol Chem* 2015;290:5028–40.
158 Butler KV, Kalin J, Brocker C, et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. *J Am Chem Soc* 2010;132:10942–6.
159 Vishwakarma S, Jey LR, Muley M, et al. Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti- rheumatic effects. *Int Immunopharmacol* 2013;16:72–8.
160 de Zoeten EF, Wang L, Butler K, et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3+ T-regulatory cells. *Mol Cell Biol* 2011;31:2066–78.
161 Haggsaty SJ, Koeller KM, Wong JC, et al. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. *Proc Natl Acad Sci U S A* 2003;100:4389–94.
162 Peeters JG, Vervoort SJ, Minnheer G, et al. Autoimmune disease-associated gene expression is reduced by BET-inhibition. *Genome Data* 2016;7:14–17.
163 Lu P, Shen Y, Yang H, et al. BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency. *Sci Rep* 2017;7:16646.
164 Kim SW, Kim ES, Moon CM, et al. Genetic polymorphisms of IL-23R and IL-17A and novel insights into their associations with inflammatory bowel disease. *Gut* 2011;60:1527–36.
165 Goswami S, Apostolou I, Zhang J, et al. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. *J Clin Invest* 2012;128:3813–8.
166 Tambwakale MM. Natural nuclear factor kappa beta inhibitors. *Inflamm Bowel Dis* 2012;18:719–23.
167 Suskind DL, Wahbeh G, Burpee T, et al. Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study. *J Pediatr Gastroenterol Nutr* 2013;56:277–89.
168 De Vries LCS, Wildenberg ME, De Jonge WJ, et al. The future of janus kinase inhibitors in inflammatory bowel disease. *J Crohns Colitis* 2017;11:885–93.